Neurocrine Biosciences (NBIX) Return on Sales [ROS] (2010 - 2026)
Neurocrine Biosciences (NBIX) reported Return on Sales [ROS] of 15.80% for Q2 2026, down 5.38 percentage points from 21.18% a year earlier and down 7.95 percentage points from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Return on Sales [ROS] (2010 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Neurocrine Biosciences' Return on Sales [ROS] came in at 23.56%, up 3.84 percentage points year-over-year; for FY2025, it was 21.64%, down 2.58 percentage points from FY2024.
- Return on Sales [ROS] has a five-year change of +6.06 percentage points (FY2020 to FY2025).
- By year, Return on Sales [ROS] came in at 24.22% in FY2024 (+10.93 pp), 13.30% in FY2023 (-3.43 pp), 16.73% in FY2022 (+7.68 pp) and 9.04% in FY2021 (-6.54 pp).
- The Q2 2026 figure ranks as the lowest quarterly Return on Sales [ROS] since Q1 2025.
- Year over year, Return on Sales [ROS] gained in four of the last eight quarters, with an average year-over-year change of -0.70 percentage points.
- The high point for year-over-year Return on Sales [ROS] in five years was Q1 2024 (a gain of 46.43 percentage points); the low point was Q4 2021 (a drop of 40.60 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at 23.74% (Q1 2026), 26.18% (Q4 2025) and 30.07% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Neurocrine Biosciences | 14.55 Bn | 10.25 Bn | 935.80 Mn | 15.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.80% |
| Mar 31, 2026 | 23.74% |
| Dec 31, 2025 | 26.18% |
| Sep 30, 2025 | 30.07% |
| Jun 30, 2025 | 21.18% |
| Mar 31, 2025 | 4.12% |
| Dec 31, 2024 | 22.62% |
| Sep 30, 2024 | 29.55% |
| Jun 30, 2024 | 24.64% |
| Mar 31, 2024 | 19.27% |
| Dec 31, 2023 | 29.17% |
| Sep 30, 2023 | 28.31% |
| Jun 30, 2023 | 16.26% |
| Mar 31, 2023 | -27.16% |
| Dec 31, 2022 | 25.10% |
| Sep 30, 2022 | 22.63% |
| Jun 30, 2022 | 14.46% |
| Mar 31, 2022 | 1.00% |
| Dec 31, 2021 | -11.63% |
| Sep 30, 2021 | 15.03% |
API Access
Neurocrine Biosciences Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();